DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30333

August 31, 2018

Aaron Siri
Sire and Glimstad, LLP
200 Park Avenue
Seventeenth Floor
New York, New York 10166
Via email: aaron@sirillp.com

Dear Mr. Siri:

This letter is our final response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of August 22, 2018, assigned #18-01022-FOIA, for the specified the slide entitled "PEP Following Laboratory Incident at CDC" and with the specified second "bullet" in the slide from the October 26, 2017 meeting of the Advisory Committee for Immunizations Practices ("ACIP").

We located the slide, and after a careful review of the slide, no information was withheld from release.

If you need any further assistance or would like to discuss any aspect of the records provided please contact either our FOIA Requester Service Center at 770-488-6399 or our FOIA Public Liaison at 770-488-6277.

Sincerely,



Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
(770) 488-6399
Fax: (404) 235-1852

18-01022-FOIA

PEP Following Laboratory Incident at CDC

- 42 individuals potential exposed to *B. anthracis* spores were recommended to receive 60 days of antimicrobials and AVA 3-dose series

- Information regarding vaccine adherence was available for all 42 individuals
  - 35 (83%) received 1st dose
  - 16 (38%) received 2nd dose
  - 14 (33%) received 3rd dose

- Reasons for stopping vaccine PEP early
  - Low perceived risk (6/13 (46%))
  - Experiencing AEs (4/13 (31%))

Nolen LD, Traxler RM, Kharod GA, Kache PA, Katharios-Lanwermeyer S, Hendricks KA, et al. Postexposure Prophylaxis After Possible Anthrax Exposure: Adherence and Adverse Events. Health Secur. 2016 Nov/Dec;14(6):419-423